Tomorrow morning there will be some last retails wanting out at any price. I will buy from them in the expectation that Brean will fade into the past as the hit piece it was and the stock will recover at least to $12.00. Thanks Brean you skunk.
.05 wins with the FDA. Check the number of less than .005 results ACAD has. The odds are incredibly in our favor. This Co. will win and so will we!!!!!!!!
" ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson's Disease Psychosis Trial with Pimavanserin
Oct 31, 2013 20:40:00 (ET)
SAN DIEGO, Oct 31, 2013 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson's disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. In the -020 Study, pimavanserin demonstrated significant and clinically meaningful benefits and was safe and well tolerated in patients with PDP. Pimavanserin significantly reduced psychosis and maintained motor control in patients with PDP. Significant benefits were also observed in exploratory measures of nighttime sleep, daytime wakefulness and caregiver burden.
"Among Parkinson's patients, psychosis causes great distress for patients and caregivers and is the leading cause of institutionalization," said Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, and lead author. "These data indicate that pimavanserin, a selective 5-HT2A inverse agonist, confers a meaningful clinical benefit in patients with PDP and has the potential to be an important new treatment option for this condition for which there is no approved therapy in the U.S."
Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale (p=0.001), which was assessed by central, independent raters. The mean change in SAPS-PD score represented a 37% improvement for pimavanserin versus 14% for placebo (p
Do we think ACAD and its 2014 catalysts will attract them ????? You bet we do.!!!!!!!
Read Aredevare aka Mr. Hauge complain that he did not get the plaque that he wanted.
"Speaking about Awards, the court filings also reveal that both Mr. Hauge , firmer ERI CTO Dr. Stover and ERI received the inaugural Sidney Loeb award for innovation by the European Desalination Society in 2006. But Mr. Hauge who did not know or attend, never received his plaque, because it was confiscated by firmer President of ERI James Medanich." Less
Mr. Hauge is bitter and he has been found guilty by the court and has nothing to sell until the appeal is over in 2 to 3 years. When he loses the appeal, he will have nothing to sell ever.
You are an obnoxious jerk and nothing more. For those who agree, please give this post a thumbs up.
This innovation award and the granting of more patents in the last 2 years than in the history of the company makes me quite comfortable with ERII being the undisputed leader in this field.
"The IET Innovation Awards celebrate the very best innovations in science, engineering and technology across the globe. Energy Recovery's commitment to developing innovative technologies is rooted in its 20 year history. Over the past two and a half years the Company has redoubled its R&D efforts, resulting in more patents filed in just the past two years than its entire history as a company. By recently adapting its principal technology to new sectors such as oil & gas, clean energy and chemical processing, Energy Recovery has once again proven that invention is at the Company's core."
Sentiment: Strong Buy
My bet is it is very good and propels the stock up. I am in and staying in. Those afraid will bail today and feed the Hedgies cheap shares. Dumb da dumb dumb.
How could he keep the alovectin trials delaying for years?? Fraud. Why would he?? To keep his fat salary coming in while hanging his investors out to dry. If you are in, it is your turn to dry.
"Allovectin caused tumors to shrink in 4.6% of patients compared to 12.3% of patients treated with chemotherapy used as a control. The difference was actually statistically significant against allovectin.
Why safety monitors allowed the allovectin study to continue even though patients were clearly being harmed was not explained.
In a secondary analysis, the median overall survival of patients treated with allovectin was 18.6 months compared to 24.1 months for patients treated with chemotherapy.
The results of the allovectin melanoma study were delayed for years, which Vical and its supporters believed was due to the vaccine helping patients live longer. "
Shameful, VJ should be jailed not fired.